Second pivotal phase 3 study Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH).
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Fedovapagon (Primary)
- Indications Nocturia
- Focus Registrational; Therapeutic Use
- Sponsors Vantia Therapeutics
- 05 Oct 2017 New trial record
- 03 Oct 2017 According to a Vantia Therapeutics media release, Data from this trial will be used to support regulatory filings for marketing approval in the US and Europe.